For contextual class comparisons, the eMC SmPCs for semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) provide authoritative information on hypersensitivity and injection site reactions associated with approved GLP-1-based agents, and are relevant reference points for clinicians managing similar symptoms in patients receiving retatrutide in a trial setting
By significantly diminishing feelings of hunger, it supports effective weight loss when used alongside proper diet and exercise
While many are turning to medications that target GLP-1 for weight loss purposes (like semaglutide medications, often used for diabetes and obesity)
This is worth knowing about not because it happens to everyone, but because if it happens to you and you do not know it is a recognised pattern, it is very easy to misattribute it to stress, burnout, or something else entirely
Retatrutide is not approved anywhere in the world for any indication
Semaglutide works through several key mechanisms: 1